FDA approves CBI-1214 for colorectal cancer, enabling fast-tracked clinical trials and highlighting innovative T-cell engager ...

Salvage Efficacy: Most significantly, for the 8 patients who showed no response to initial TCE monotherapy, the addition of ...

BGB-B2033, a bispecific antibody, targets 4-1BB and GPC3, showing potential in advanced hepatocellular carcinoma (HCC) ...

Findings from a study on the utility of ultrasensitive circulating tumor DNA (ctDNA) as a predictive biomarker for patients ...

Liquid biopsy using ctDNA refines risk stratification for patients with residual cancer burden post-neoadjuvant therapy, ...

Laura Huppert, MD, highlights patient-reported outcomes from the phase 3 ASCENT-04 trial which compared first-line treatment ...

Laura Huppert, MD, discusses the results of the phase 3 ASCENT-03 trial, which compared the antibody-drug conjugate ...

Pelareorep (Reolysin), an intravenously delivered oncolytic virus immunotherapy, has demonstrated positive second-line ...

Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key ...

Michael Wang, MD, professor at The University of Texas MD Anderson Cancer Center, details the rationale for a long-term ...

Combination therapy with nogapendekin alfa inbakicept and BCG achieved a 3-year DSS rate of 96% in BCG-unresponsive NMIBC ...

HER2CLIMB-05 successfully met its primary endpoint of progression-free survival (PFS), with the addition of tucatinib ...